EU approval for Sanofi’s diabetes combo
Sanofi-Aventis’ Suliqua has been approved in the European Union expanding treatment options for people with type II diabetes.
Read More
Tag: lixisenatide
Sanofi’s new diabetes combo hits PhIII targets
A new diabetes combination therapy being developed by Sanofi has hit targets in two pivotal Phase III studies, showing a superior reduction in blood glucose compared to insulin glargine and versus lixisenatide.
Read More
FDA advisors back approval of Sanofi’s new diabetes drug
Sanofi’s new diabetes therapy has taken a big step towards clearance in the US after winning backing from regulatory advisors.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
